Artiva Biotherapeutics, Inc. Cash Flow Statement
ARTV|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Artiva Biotherapeutics, Inc. used $77M in operating cash flow and negative free cash flow of $79M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$83.9M | -$28.7M |
| Depreciation & Amortization | $2.6M | $2.3M |
| Operating Cash Flow | -$76.8M | -$47.4M |
| Capital Expenditures | $2.6M | $3.3M |
| Free Cash Flow | -$79.3M | -$50.7M |
| FCF Margin | - | -151.3% |